Paraprosdokian
Established Member (Voting Rights)
A large company specialising in umbilical cord blood has conducted a successful phase 2a trial in Long Covid patients (20 LC patients, 10 controls). The UCB contains Haemopoietic Progenitor Cells (which are the things that form from stem cells before they turn into blood cells). See here for an overview.
It was found to be safe with lower treatment-emergent adverse events (primary endpoint) and to reduce fatigue as measured by the Chalder scale.
Based on a press release, its difficult to tell how successful it was. They don't say how much the Chalder fatigue scores fell, only that 85% of patients in the treatment arm fell below a score of 4 (compared to 20% in the control arm). Who knows if the threshold of 4 was a pre-determined benchmark or the nicest way to present the numbers to the market. The company is being listed on the Taiwan stock exchange this month.
The FDA, however, seem to think this is promising. It's granted Regenerative Medicine Advanced Therapy (RMAT) designation to UCB for the use in LC on the strength of these results. It's a fast track for novel treatments for serious illnesses.
I think its a possible path forward. Perhaps the UCB is regenerating white blood cells and that is causing improvement. Or perhaps someone thought "stem cells regenerate things, let's roll the dice and cross our fingers that it works".
Link to press release announcing phase 2 results: https://www.prnewswire.com/news-rel...e-relief-from-fatigue-symptoms-302336656.html
Link to clinical trial: https://clinicaltrials.gov/study/NCT05682560
Edit: Fixed a typo
It was found to be safe with lower treatment-emergent adverse events (primary endpoint) and to reduce fatigue as measured by the Chalder scale.
Based on a press release, its difficult to tell how successful it was. They don't say how much the Chalder fatigue scores fell, only that 85% of patients in the treatment arm fell below a score of 4 (compared to 20% in the control arm). Who knows if the threshold of 4 was a pre-determined benchmark or the nicest way to present the numbers to the market. The company is being listed on the Taiwan stock exchange this month.
The FDA, however, seem to think this is promising. It's granted Regenerative Medicine Advanced Therapy (RMAT) designation to UCB for the use in LC on the strength of these results. It's a fast track for novel treatments for serious illnesses.
I think its a possible path forward. Perhaps the UCB is regenerating white blood cells and that is causing improvement. Or perhaps someone thought "stem cells regenerate things, let's roll the dice and cross our fingers that it works".
Link to press release announcing phase 2 results: https://www.prnewswire.com/news-rel...e-relief-from-fatigue-symptoms-302336656.html
Link to clinical trial: https://clinicaltrials.gov/study/NCT05682560
Edit: Fixed a typo
Last edited: